Literature DB >> 19168169

Circulating angiogenic factors in gestational proteinuria without hypertension.

Alexander M Holston1, Cong Qian, Kai F Yu, Franklin H Epstein, S Ananth Karumanchi, Richard J Levine.   

Abstract

OBJECTIVE: Our goal was to determine whether obstetric outcomes and serum angiogenic factors are altered in women with gestational proteinuria without hypertension. STUDY
DESIGN: We performed a nested case-control study of 108 women with gestational proteinuria and compared them with 1564 randomly selected women with normotension without proteinuria during pregnancy (control subjects) and with 319 women who experienced preeclampsia.
RESULTS: Women with gestational proteinuria had greater body-mass index and higher blood pressure at study enrollment. Adverse obstetric outcomes were infrequent. Levels of free placental growth factor were lower than control levels beginning early in gestation. Compared with gestational-age matched control subjects, free placental growth factor was reduced beginning 6-8 weeks before proteinuria. Although soluble fms-like tyrosine kinase 1 and soluble endoglin concentrations were elevated 1-2 weeks before proteinuria, these elevations were modest and transient. After the onset of proteinuria, angiogenic factor levels generally did not differ significantly from control levels.
CONCLUSION: Gestational proteinuria in healthy nulliparous women appears to be a mild variant of preeclampsia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168169      PMCID: PMC2679962          DOI: 10.1016/j.ajog.2008.10.033

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  32 in total

1.  Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice.

Authors:  Virginie Mattot; Lieve Moons; Florea Lupu; Daniel Chernavvsky; R Ariel Gómez; Désiré Collen; Peter Carmeliet
Journal:  J Am Soc Nephrol       Date:  2002-06       Impact factor: 10.121

2.  Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1.

Authors:  Duk-Hee Kang; Alison H Joly; Se-Woong Oh; Christian Hugo; Dontscho Kerjaschki; Katherine L Gordon; Marilda Mazzali; J Ashley Jefferson; Jeremy Hughes; Kirsten M Madsen; George F Schreiner; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2001-07       Impact factor: 10.121

3.  Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

Authors:  Vera Eremina; Manish Sood; Jody Haigh; András Nagy; Ginette Lajoie; Napoleone Ferrara; Hans-Peter Gerber; Yamato Kikkawa; Jeffrey H Miner; Susan E Quaggin
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

4.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

5.  Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria.

Authors:  Hikaru Sugimoto; Yuki Hamano; David Charytan; Dominic Cosgrove; Mark Kieran; Akulapalli Sudhakar; Raghu Kalluri
Journal:  J Biol Chem       Date:  2003-01-21       Impact factor: 5.157

6.  Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia.

Authors:  Kaori Koga; Yutaka Osuga; Osamu Yoshino; Yasushi Hirota; Xie Ruimeng; Tetsuya Hirata; Satoru Takeda; Tetsu Yano; Osamu Tsutsumi; Yuji Taketani
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

7.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

8.  A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.

Authors:  Roberto Romero; Jyh Kae Nien; Jimmy Espinoza; David Todem; Wenjiang Fu; Hwan Chung; Juan Pedro Kusanovic; Francesca Gotsch; Offer Erez; Shali Mazaki-Tovi; Ricardo Gomez; Sam Edwin; Tinnakorn Chaiworapongsa; Richard J Levine; S Ananth Karumanchi
Journal:  J Matern Fetal Neonatal Med       Date:  2008-01

9.  Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies.

Authors:  Robert N Taylor; Jane Grimwood; Rennae S Taylor; Michael T McMaster; Susan J Fisher; Robyn A North
Journal:  Am J Obstet Gynecol       Date:  2003-01       Impact factor: 8.661

10.  Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia.

Authors:  Bruno M Polliotti; A Gordon Fry; Devereux N Saller; Robert A Mooney; Christopher Cox; Richard K Miller
Journal:  Obstet Gynecol       Date:  2003-06       Impact factor: 7.661

View more
  7 in total

1.  Spot urine protein measurements in normotensive pregnancies, pregnancies with isolated proteinuria and preeclampsia.

Authors:  Andrea Kattah; Natasa Milic; Wendy White; Vesna Garovic
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-07-26       Impact factor: 3.619

2.  Midpregnancy levels of angiogenic markers in relation to maternal characteristics.

Authors:  Renée S Mijal; Claudia B Holzman; Sarosh Rana; S Ananth Karumanchi; Jianling Wang; Alla Sikorskii
Journal:  Am J Obstet Gynecol       Date:  2010-12-10       Impact factor: 8.661

3.  Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Steven J Korzeniewski; Josef M Cortez; Athina Pappas; Adi L Tarca; Piya Chaemsaithong; Zhong Dong; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2013-08-08

4.  Circulating anti-angiogenic factors during hypertensive pregnancy and increased risk of respiratory distress syndrome in preterm neonates.

Authors:  Alice Wang; Alexander M Holston; Kai F Yu; Jun Zhang; Mourad Toporsian; S Ananth Karumanchi; Richard J Levine
Journal:  J Matern Fetal Neonatal Med       Date:  2011-12-13

5.  Relationships of risk factors for pre-eclampsia with patterns of occurrence of isolated gestational proteinuria during normal term pregnancy.

Authors:  Corrie Macdonald-Wallis; Debbie A Lawlor; Jon Heron; Abigail Fraser; Scott M Nelson; Kate Tilling
Journal:  PLoS One       Date:  2011-07-18       Impact factor: 3.240

6.  Serum biomarkers for the prediction and diagnosis of preeclampsia: A meta-analysis.

Authors:  Ruqaiya Shahid; Muhammad F Bari; Mehwish Hussain
Journal:  J Taibah Univ Med Sci       Date:  2021-08-11

7.  Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study.

Authors:  Richard J Levine; Lars J Vatten; Gary L Horowitz; Cong Qian; Pal R Romundstad; Kai F Yu; Anthony N Hollenberg; Alf I Hellevik; Bjorn O Asvold; S Ananth Karumanchi
Journal:  BMJ       Date:  2009-11-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.